Endothelial monocyte activating polypeptide II (EMAP II) is a proinflammatory cytokine with
antiangiogenic properties. EMAP II functions as a potent inhibitor of primary and metastatic
tumor growth, has strong inhibitory effects on endothelial cells (ECs), and can reduce
intratumoral expression of the angiogenesis inducer vascular endothelial growth factor
(VEGF). VEGF influences EC functions such as proliferation, migration, survival and tube
formation. Therapeutic strategies that target VEGF have been demonstrated to reduce the …